Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod.
An official website of the United States government
A .gov website belongs to an official government organization in the United States.
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
View All Announcements
COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have mild to moderate COVID-19 symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on health care facilities, and even save lives. For details on patient eligibility, see the Side-by-Side Overview of Therapeutics Authorized or Approved for the Treatment of Mild to Moderate COVID-19.
HHS/ASPR purchased supplies of COVID-19 therapeutic products for outpatient use. Now that these products have transitioned to commercial market, HHS continues to work with state and territorial health departments as well as national health care and medical organizations and associations to maximize access to COVID-19 treatments.
On November 1, 2023, Lagevrio and Paxlovid became commercially available, and patient assistance programs are now available for eligible individuals. To learn more about these programs and about HHS distribution timelines of HHS-procured inventory, please see Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program.
Find COVID-19 Medications
Patient Assistance Programs for COVID-19 Therapeutics
COVID-19 Therapeutic Product Expiration
Thresholds, Orders, and Replenishment by Jurisdiction
Federal Response to COVID‑19: Therapeutics Clinical Implementation Guide
Side-by-Side Overview: Outpatient Therapies Authorized for Treatment of Mild-Moderate COVID-19
COVID-19 Therapeutics Decision Aid
Information for Long‑Term Care Facilities
Federal Retail Pharmacy Therapeutics Program
Social Media Digital Toolkit
Sunsetting the US Government COVID-19 Therapeutics Distribution Program
Test to Treat
People who are moderately or severely immunocompromised, are aged 12 and older, and who weigh at least 88 pounds may be eligible to get Pemgarda (pemivibart), a monoclonal antibody authorized to help protect against COVID-19. Pemgarda is not a treatment for COVID-19.
